机构：[1]Department of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.中山大学附属第三医院[2]Sungen Bioscience Co. Ltd., Shantou, China.[3]Department of Pharmacy, Shenyang Red Cross Hospital, Shenyang, China.[4]Guangzhou Center, Sinopharm Group Pharmaceutical Co., Ltd., Guangzhou, China.[5]Antithrombotic & Thrombolytic Innovative Drug Research Center, Shenyang Pharmaceutical University, Shenyang, China.[6]The Central Laboratory, First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.[7]School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia.
第一作者机构：[1]Department of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
推荐引用方式(GB/T 7714)：
Chen Hongjie,Chen Jiepeng,Zhang Fuping,et al.Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants[J].Frontiers in cardiovascular medicine.2022,9:1076420.doi:10.3389/fcvm.2022.1076420.
APA：
Chen Hongjie,Chen Jiepeng,Zhang Fuping,Li Yuanhui,Wang Ronghua...&Lin Yiguang.(2022).Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants.Frontiers in cardiovascular medicine,9,
MLA：
Chen Hongjie,et al."Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants".Frontiers in cardiovascular medicine 9.(2022):1076420
